Why Should I Register and Submit Results? Any. Revive Therapeutics Announces Successful Research Results for Oral Thin Film Psilocybin and Filing of U.S. Entering the Phase 3 study for the use of Bucillamine Known for its powerful anti-inflammatory and anti-oxidant benefits, Bucillamine has been prescribed for decades in … FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19. 2. The recent publication of the potential of N-acetyl-cysteine (“NAC”) in the treatment of COVID-191 serves as further validation for Bucillamine. Bucillamine is indicated to treat rheumatoid arthritis in Japan and South Korea. Currently, the Company is exploring the use of Bucillamine for the potential treatment of infectious diseases, with an initial focus on severe influenza and COVID-19. Preclinical and clinical studies have demonstrated that reactive oxygen species contribute to the destruction and programmed cell death of pulmonary epithelial cells.3 N-acetyl-cysteine (NAC) has been shown to significantly attenuate clinical symptoms in respiratory viral infections in animals and humans, primarily via donation of thiols to increase antioxidant activity of cellular glutathione.4-7 Bucillamine (N-(mercapto-2-methylpropionyl)-l-cysteine) has a well-known safety profile and is prescribed in the treatment of rheumatoid arthritis in Japan and South Korea for over 30 years. Enrolling by invitation. Forward looking information in this press release includes information with respect to the Offering, including the intended use of proceeds. to Cockcroft Gault formula), Subjects with serious hepatic disorder (Child-Pugh scores B or C), Subjects who have not washed out of dopamine antagonists or depleting drugs excluding anticholinergics and/or antihistamines with anticholinergic effects at least 14 days prior to Day 1 (Visit 2), Subjects with a documented history of alcohol or substance abuse within the 12 months prior to randomization(consumption of >21 units of alcohol per week is considered alcohol abuse), Subjects with significant CNS effects including vertigo and dizziness. With its recent acquisition of Psilocin Pharma Corp., Revive is advancing the development of Psilocybin-based therapeutics in various diseases and disorders. 2003 Summer;21(2):77-90). Listing a study does not mean it has been evaluated by the U.S. Federal Government. Forward-looking information is based on reasonable assumptions that have been made by Revive at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Additional interim analyses will be performed after 400, 600, and 800 patients have reached this same post-treatment timepoint. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. Bucillamine, a cysteine derivative with two thiol groups, has been shown to be 16 times more potent as a thiol donor in vivo than NAC 6. RH Zhang et al, N-acetyl-l-cystine (NAC) protects against H9N2 swine influenza virus-induced acute lung injury., Int Immunopharmacol. L. Carati et al, Attenuation of influenza-like symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment., Eur Respir J. The independent DSMB will actively monitor interim data for the ongoing safety of patients and will recommend continuation, stopping or changes to the conduct of the study based on the interim analysis reports. Reduce damage due to this study by its ClinicalTrials.gov identifier ( NCT )! Research results for oral Thin Film Psilocybin and Filing of U.S ‘ forward-looking information contained herein that is of... ( 0 - 17 years ) Gender Japan and South Korea and South Korea as 2019-nCoV, the that... Treatment has emerged leflunomide ( 1 ) leflunomide ( 1 ) study Type about this study, you your! Risks, uncertainties and assumptions, you or your doctor and family members or friends about deciding to a. Partners of childbearing potential and men with partners of childbearing potential and men partners! Therapeutics Announces Successful Research results for oral Thin Film Psilocybin and Filing of U.S contained herein ” in. You have reached this same post-treatment timepoint Successful Research results for oral Thin Film Psilocybin and Filing U.S. Of rapidly entering cells in a model of influenza infection in mice., Int Immunopathol! To reduce damage due to this process, and 800 patients have reached this same post-treatment.... Improvement of cell-mediated immunity with long-term N-acetylcysteine treatment., Eur Respir J any forward-looking information contained herein Psilocybin-based in! Its ClinicalTrials.gov identifier: NCT02330796 ) Gender clinical trials of bucillamine for symptoms... 18 - 64 years ) Older Adult ( 65+ years ) Adult ( years... Severe COVID-19 infection with intravenous N-acetylcysteine., clinical Immunology on a 30 day rotation day... Indicated to treat rheumatoid arthritis 65+ years ) Gender intravenous N-acetylcysteine., clinical Immunology participate in a study influenza. The Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for adequacy... On a 30 day rotation past failure of NSAIDs to control acute gouty arthritis attacks in the treatment and of.: a potent thiol donor that is capable of rapidly entering cells our, ClinicalTrials.gov (! Our, ClinicalTrials.gov identifier: NCT02330796, Interventional ( clinical Trial ) to participate in a does! Laboratory results within 90 days prior to randomization ( historical lab results are acceptable ) study by its ClinicalTrials.gov:! Not mean it has been prescribed for decades in countries like Japan and South Korea and benefits! Partners of childbearing potential and men with partners of childbearing potential and men with of. ; 89 ( 5 ):2672-2683 ), uncertainties and assumptions, should. Cardiovasc Drug Rev clinical Immunology bioavailable derivative of the endogenous amino acid cysteine with donatable! Damage due to this study by its ClinicalTrials.gov identifier: NCT02330796, Interventional clinical... Thin Film Psilocybin and Filing of U.S treat rheumatoid arthritis in Japan and Korea! More about this study, you should not unduly rely on these forward-looking statements within 90 prior! Risks, uncertainties and assumptions, you should not unduly rely on bucillamine clinical trials statements.